1. Fourth-quarter sales for fiscal year 2023 grew 5.6 percent, according to a news release. The results come from strong performances in cardiovascular, medical-surgical and neuroscience business, Medtronic said.
2. Full-year sales were down 1.4 percent, which the company said was a result of “continued unfavorable macroeconomic impact of foreign currency translation and inflation.”
3. Medtronic’s neuroscience portfolio saw $2.4 billion in sales in the fourth quarter, a 4.8 percent year-over-year increase. Cranial and spinal technologies saw a 2.8 percent increase year over year with $1.2 billion in revenue.
4. Medtronic projects its fiscal year 2024 sales to grow 4 percent to 4.5 percent.
5. The company also said it plans to acquire EOFlow, a company known for its EO Patch for insulin delivery.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.